A-SKIN has received approval of the National Health Inspection IGZ to distribute Tiscover, KC-Matrix and acellular dermis (AS210) for clinical use in selected patients. The permission was granted on the basis of the favorable preliminary safety and efficacy data and, regarding Tiscover and KC-Matrix, also the National and EU Hospital Exemption regulation. Both latter products, therefore, can be administered only to limited numbers of patients. Reimbursement of the costs is still negotiated, but costs will not exceed production costs.     

Back to top